The Moffitt requests $248,588 in annual direct costs for support of Administration personnel, totaling 2.10 FTE. The budget request represents less than 4% of the total CCSG request and is less than 1% of Moffitt's total Research Administration operational budget. Since all research activities at Moffitt are cancer-related, support of research is in direct support of the Cancer Center Support Grant and is composed of three primary functions: Program Administration, Shared Resource Oversight, and Research Administration. Program administrative support is provided at the division level (Basic Science, Prevention &Control, Translational Science, and Clinical Investigations) with dedicated staff led by a Division Administrator who provides support for the programs and faculty within their division. Shared Resource Oversight occurs through alignment and allocation of functions to specific administrative groups: Laboratory Operations;Clinical Trials Office;Tissue;and Cell Therapies. Research Administration represents a collection of Offices that provide a range of support activities including: Institutional Support Services;Sponsored Research;Grant and Contract Accounting;Research Costs Analysis;Clinical Trials Finance;Protocol Review and Support;and Institutional Regulatory Affairs. The administration of research activities for the Cancer Center is organized under Michael Benedict, PharmD, who reports to Dr. Dalton through the Director of the Moffitt Research Institute (MRI) and Associate Center Director for Cancer Prevention and Control, Dr. Sellers. In addition to reporting to the Director of the MRI, Dr. Benedict has functional responsibilities to all Associate Center Directors. Leadership has changed since the last submission. Dr. Benedict, was recruited back to the Cancer Center to serve as Vice President for Clinical Investigations, and in July 2009, was appointed the sole Vice President for Research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA076292-15W2
Application #
8723481
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$49,999
Indirect Cost
$20,326
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Chung, Brile; Stuge, Tor B; Murad, John P et al. (2014) Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep 8:871-82
Charbonneau, Bridget; Block, Matthew S; Bamlet, William R et al. (2014) Risk of ovarian cancer and the NF-*B pathway: genetic association with IL1A and TNFSF10. Cancer Res 74:852-61
Unrod, Marina; Simmons, Vani N; Sutton, Steven K et al. (2014) A randomized clinical trial of self-help intervention for smoking cessation: research design, interventions, and baseline data. Contemp Clin Trials 38:284-90
Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256
Padron, Eric; Yoder, Sean; Kunigal, Sateesh et al. (2014) ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood 123:3675-7
Hampras, Shalaka S; Viscidi, Raphael P; Helzlsouer, Kathy J et al. (2014) Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev 23:2591-6
Chen, Ning; Chon, Hye Sook; Xiong, Yin et al. (2014) Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep 31:376-83
Molife, L Rhoda; Yan, Li; Vitfell-Rasmussen, Joanna et al. (2014) Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol 7:1
Carvalho, Renato S; Fernandes, Vanessa C; Nepomuceno, Thales C et al. (2014) Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther 15:840-50
Rizwani, Wasia; Schaal, Courtney; Kunigal, Sateesh et al. (2014) Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One 9:e100888

Showing the most recent 10 out of 108 publications